Patents by Inventor Ching-Shih Chen

Ching-Shih Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11117888
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: September 14, 2021
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • Publication number: 20210221801
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Application
    Filed: January 22, 2020
    Publication date: July 22, 2021
    Applicant: China Medical University
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • Publication number: 20210163453
    Abstract: Disclosed herein are compounds, compositions, and methods for inhibiting mitochondrial oxygen consumption in a cancerous tissue. The compounds, compositions, and methods can be used to treat a subject with hypoxic cancerous tissue.
    Type: Application
    Filed: July 23, 2019
    Publication date: June 3, 2021
    Inventors: Nicholas DENKO, Ioanna PAPANDREOU, Martin BENEJ, Ching-Shih CHEN, Sandip VIBHUTE
  • Publication number: 20200289438
    Abstract: In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
    Type: Application
    Filed: September 13, 2018
    Publication date: September 17, 2020
    Inventors: Ching-Shih Chen, Christopher C. Coss, Samuel Kulp, Yu-Chou Tseng, Tanios Bekaii-Saab
  • Patent number: 9598364
    Abstract: Indolyl or indolinyl compounds of formula (I): wherein bond, n, R1, R2, R3, R4, R5, and R6, are defined herein. Also disclosed is a method for treating cancer with these compounds.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: March 21, 2017
    Assignees: Taipei Medical University, Ohio State University, National Taiwan University
    Inventors: Ching-Shih Chen, Jing-Ping Liou, Hsing-Jin Liu, Kuo-Sheng Hung, Pei-Wen Shan, Wen-Ta Chiu, Che-Ming Teng
  • Patent number: 9457031
    Abstract: Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as Myocobacteria tuberculosis.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: October 4, 2016
    Inventors: Ching-Shih Chen, Santosh Salunke, Larry Schlesinger, Abul K. Azad
  • Patent number: 9174951
    Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: November 3, 2015
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Patent number: 9156790
    Abstract: Compounds according to formula I: wherein Ar is a fused aryl group, R1 is selected from alkyl and aryl amides, CF3, and CH2OH, and R2 is selected from hydrogen, —C(?O)CH2NH2, and —C(?O)CH2CH2NH2 are described. The compounds are effective for inhibiting p21-activated kinases, and can be used for prevention and treatment of cancer.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: October 13, 2015
    Assignee: Ohio State Innovation Foundation
    Inventors: Ching-Shih Chen, Matthew David Ringel, Motoyashi Saji, Yihui Ma
  • Publication number: 20150258100
    Abstract: Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as Myocobacteria tuberculosis.
    Type: Application
    Filed: July 30, 2013
    Publication date: September 17, 2015
    Inventors: Ching-Shih Chen, Santosh Salunke, Larry Schlesinger, Abul K. Azad
  • Patent number: 9115090
    Abstract: Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: August 25, 2015
    Assignee: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventor: Ching-Shih Chen
  • Patent number: 9079899
    Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: July 14, 2015
    Assignee: THE OHIO STATE UNIVERSITY
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20150150832
    Abstract: Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.
    Type: Application
    Filed: November 19, 2014
    Publication date: June 4, 2015
    Inventors: Ching-Shih Chen, Tanios Bekaii-Saab, Denis Guttridge, Guido Marcucci, Samuel Kulp, Yu-Chou Tseng
  • Publication number: 20150051255
    Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.
    Type: Application
    Filed: March 28, 2013
    Publication date: February 19, 2015
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20140364477
    Abstract: Indolyl or indolinyl compounds of formula (I): wherein bond, n, R1, R2, R3, R4, R5, and R6, are defined herein. Also disclosed is a method for treating cancer with these compounds.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Applicants: Ohio State University, National Taiwan University
    Inventors: Ching-Shih Chen, Jing-Ping Liou, Hsing-Jin Liu, Kuo-Sheng Hung, Pei-Wen Shan, Wen-Ta Chiu, Che-Ming Teng
  • Publication number: 20140323538
    Abstract: Compounds according to formula I: wherein Ar is a fused aryl group, R1 is selected from alkyl and aryl amides, CF3, and CH2OH, and R2 is selected from hydrogen, —C(?O)CH2NH2, and —C(?O)CH2CH2NH2 are described. The compounds are effective for inhibiting p21-activated kinases, and can be used for prevention and treatment of cancer.
    Type: Application
    Filed: March 31, 2014
    Publication date: October 30, 2014
    Applicant: Ohio State Innovation Foundation
    Inventors: Ching-Shih Chen, Matthew David Ringel, Motoyashi Saji, Yihui Ma
  • Patent number: 8846748
    Abstract: Indolyl or indolinyl compounds of formula (I): wherein bond, n, R1, R2, R3, R4, R5, and R6, are defined herein. Also disclosed is a method for treating cancer with these compounds.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: September 30, 2014
    Assignees: Taipei Medical University, Ohio State University, National Taiwan University
    Inventors: Ching-Shih Chen, Jing-Ping Liou, Hsing-Jin Liu, Kuo-Sheng Hung, Pei-Wen Shan, Wen-Ta Chiu, Che-Ming Teng
  • Patent number: 8741944
    Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 3, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang
  • Patent number: 8680133
    Abstract: Compounds and methods for treating cancer or inducing apoptosis in proliferating cells. The compounds are shown in formula I: wherein X is selected from hydroxyl, thiol, and amino; Y is selected from carboxyl and sulfonyl; R1, R2, R3, and R4 are selected from hydrogen, lower alkyl, and combinations thereof; R5, R6, and R7 are selected from hydrogen, halo, ni tro, amino, methoxy, and combinations thereof; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: March 25, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Jing-Ru Weng
  • Patent number: 8658647
    Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 25, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp
  • Publication number: 20140031388
    Abstract: Anticancer compounds according to formula I are described herein. wherein R1, R2, R3 and R4 are selected from H, CH3, OH, SH, OCH3, NHR?, halogen, CF3, N-linked pyrrolidine, and SO2NHR?, or any combination thereof; R5 is an alkyl, alkenyl, or alkaryl group including from 4 to 11 carbons, X is selected from CH2, CHOH, C?O, S?O, O?S?O, and an oxetane ring, Y is selected from CH2, O, and NH, and R? is a H, aryl, or a lower alkyl group, or pharmaceutically acceptable salts thereof. The compounds have been shown to facilitate site-specific dephosphorylation of Akt at Ser-473, thereby inactivating Akt and decreasing dysregulation of Akt signaling that can occur in cancer cells.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 30, 2014
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp